Novartis loses Glivec patents case in India


The apex Indian court rejected Swiss based pharmaceutical company Novartis AG’s plea for retaining patent of its cancer drug Glivec. The development has the potential for better prospects for Indian pharmaceutical firms over well placed foreign brands. According to analysts, the Supreme Court has set a legal precedent with this decision where it refuses toContinue reading “Novartis loses Glivec patents case in India”